Marksans Pharma Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/04sfll8qzzyk2kv0aqu1qqz7.pdf

Key Takeaways


Teva Facility Integration

Mark Saldanha: "I wish it was like a Ferrari where you start from a zero to 100 in 4 seconds, but it does not happen that way."

Margin Recovery & Cost Normalization


Pricing & Market Environment

Mark Saldanha: "Whenever raw materials change, pricing erodes so fast it's never encouraging because it creates panic and even the front-end witnesses that price erosion to some extent."

Product Pipeline & R&D Strategy Shift

Mark Saldanha: "Historically, we avoided or we basically restrained from going into such complexities because it's high-risk, high-gain strategy, but we were very conservative with our outlook and our cash flow."

Capital Allocation & Inorganic Strategy

Mark Saldanha: "If history has to say something about us, we are very choosy in how we go about doing our inorganic strategies and how we acquire companies."

Guidance & Commitments

CommitmentSpecificsTimeline
Teva plant revenue startMeaningful revenue contribution to beginQ3 FY24
Teva plant net profit breakevenBreakeven expectedQ3 FY24
Teva plant full optimizationFull-fledged revenue generationQ1 FY25
Teva plant volume target500 crore-plus tabletsFY25
Teva plant capexINR150-200 crores per yearFY24 and FY25
Revenue milestoneCross INR2,000 crores, then a new undisclosed benchmark beyondComing years
EBITDA margin floorMaintain at least 18%FY24
EBITDA margin ambitionAim to touch 20%FY24
Capital return policyOne-third of free cash flow to dividends and/or buybackAnnual process
DMF filingsFive molecules to be filedAround September 2023
API backward integrationOwn license incorporation after DMF filingThree to four months post-filing (H2 FY24)
New product filings from Teva plantFirst filings to see lightMid-FY25
Tax rateEffective tax rate ~23%FY24 onward

Key Metrics

MetricQ4 FY23
Operating revenue₹486 cr, +16.3% YoY
US and North America revenue₹193.5 cr, +12.8% YoY
UK and EU Formulation revenue₹206.3 cr, +33.1% YoY
Gross profit₹242.1 cr, +17.3% YoY
Gross margin49.8%, +40 bps YoY from 49.4%
EBITDA₹109.5 cr, +72.1% YoY
EBITDA margin22.5%, +730 bps YoY from 15.2%
Profit after tax₹82.7 cr, +178.9% YoY
Full-year FY23 operating revenue₹1,852 cr, +24.2% YoY
Full-year FY23 EBITDA margin18.3%, +100 bps YoY from 17.4%
Full-year FY23 PAT₹265 cr, +42% YoY
Full-year FY23 EPS₹6.4 per share, +42% YoY
Full-year FY23 free cash flow₹183.8 cr
Cash and equivalents~₹715 cr
US OTC proportion of US business~74–75%, up from ~55%
Existing capacity utilization (excl. Teva)70%
Teva facility target volume (FY25)500 crore-plus tablets or pills
Teva facility total investment (incl. acquisition)₹200 cr; acquisition cost ₹56 cr, balance ₹144 cr for capacity expansion
Freight cost, US containers~$3,000 per container, down from peak of $12,500
Freight cost, UK containers~$2,000 per container, down from peak of $9,000
Effective tax rate guidance (FY24)~23%, up from 21% in FY23 due to UK corporate tax rate increase from 20% to 25%
Dividend announced (FY23)₹0.5 per share, 50% of face value of ₹1 each